- Published on
Infectious Disease and Microbiology -Pneumocystis jiroveci (Carinii) Infection
Pneumocystis jiroveci is an opportunistic fungal pathogen whose natural habitat is the lung. It is an important cause of pneumonia in immunocompromised patients, especially individuals with HIV/AIDS. The disease is commonly referred to as Pneumocystis pneumonia (PCP). Although formerly known as Pneumocystis carinii, the organism infecting humans is now correctly termed Pneumocystis jiroveci. Despite advances in prophylaxis and antiretroviral therapy, PCP remains one of the most common opportunistic infections in HIV-infected patients.
The incidence of PCP has decreased substantially because of routine prophylaxis and improved HIV management. However, it still occurs frequently among patients with advanced immunosuppression. PCP has also been reported in patients receiving immunomodulatory therapies such as infliximab and etanercept. Extrapulmonary disease is uncommon, occurring in fewer than 3% of cases. Internationally, the reported incidence is considered low, although this is likely due to underdiagnosis. PCP is particularly important in HIV-infected infants, among whom it is responsible for a large proportion of pneumonia cases.
Major risk factors include HIV/AIDS with CD4 counts below 200/mm³, malignancy, long-term corticosteroid or immunosuppressive therapy, primary immunodeficiency syndromes, tobacco use, and severe malnutrition. Patients with organ transplants, hematologic malignancies, and severe combined immunodeficiency are also at increased risk. Because of these risks, prophylaxis is recommended for high-risk HIV-infected individuals and certain other immunocompromised populations.
Primary prophylaxis is indicated in HIV-infected patients with CD4 counts below 200/mm³ or in those with oropharyngeal candidiasis regardless of CD4 count. The preferred prophylactic regimen is one double-strength tablet of trimethoprim-sulfamethoxazole daily. Alternative regimens include reduced-dose TMP-SMX, dapsone-based regimens, nebulized pentamidine, or pyrimethamine combinations. Secondary prophylaxis is recommended for all patients recovering from PCP until immune reconstitution occurs.
Infection with P. jiroveci usually occurs early in childhood, and many healthy individuals harbor the organism in their lungs without disease. In immunocompromised hosts, defective cellular immunity—especially impaired CD4 T-cell function—prevents effective clearance of the organism. Activated macrophages become unable to eliminate the fungus, resulting in increased alveolar-capillary permeability and impaired gas exchange. This process produces hypoxemia, respiratory alkalosis, and diffuse interstitial pneumonia.
Patients usually present with nonspecific symptoms such as progressive exertional dyspnea, fever, dry cough, chest discomfort, chills, and weight loss. In HIV-infected individuals, the illness often develops gradually over days to weeks, whereas in non-HIV immunocompromised patients the disease may progress rapidly and severely. Hemoptysis is uncommon but may occur.
On physical examination, patients commonly have tachypnea, fever, and tachycardia. Pulmonary examination may be surprisingly normal in up to half of patients despite significant hypoxemia. Children with severe disease may exhibit cyanosis, nasal flaring, and intercostal retractions. Rare extrapulmonary manifestations can involve the central nervous system, thyroid, gastrointestinal tract, lymph nodes, eyes, and bone marrow.
Laboratory findings are nonspecific. Elevated lactate dehydrogenase (LDH) levels are common but not diagnostic. Serum β-D-glucan levels are frequently elevated. Arterial blood gas analysis typically demonstrates hypoxemia, respiratory alkalosis, and an increased alveolar–arterial oxygen gradient. Disease severity is often classified according to the degree of alveolar–arterial gradient elevation.
Chest radiography classically demonstrates bilateral diffuse perihilar infiltrates, although early disease may show a normal chest x-ray. Chest CT scanning is more sensitive and commonly reveals diffuse bilateral ground-glass opacities. Patients receiving aerosolized pentamidine prophylaxis may show upper-lobe infiltrates and are at increased risk for pneumothorax.
Definitive diagnosis requires identification of the organism in respiratory specimens. Fiberoptic bronchoscopy with bronchoalveolar lavage remains the diagnostic standard. Induced sputum may be used but has variable sensitivity. Histopathologic stains such as methenamine silver, toluidine blue, Giemsa, and immunofluorescent stains are used to identify cysts and trophozoites. More invasive procedures such as transbronchial biopsy or open-lung biopsy are reserved for difficult cases.
The differential diagnosis includes other causes of diffuse pneumonia and respiratory failure, including tuberculosis, cytomegalovirus pneumonia, viral pneumonias, Legionella infection, fungal pneumonias, pulmonary embolism, ARDS, congestive heart failure, and pulmonary involvement by Kaposi sarcoma or lymphoma.
Trimethoprim-sulfamethoxazole (TMP-SMX) is the treatment of choice for PCP. The recommended dose is 15–20 mg/kg/day of the trimethoprim component, administered orally or intravenously in divided doses. Treatment duration is 21 days in HIV-infected patients and 14 days in non-HIV patients. Clinical improvement usually occurs within several days, although clinicians should wait at least 4–8 days before concluding treatment failure.
Adjunctive corticosteroids significantly improve survival in patients with moderate to severe disease, particularly in HIV-associated PCP. Steroids are indicated in patients with a PaO₂ below 70 mm Hg or an alveolar–arterial gradient greater than or equal to 35 mm Hg. Prednisone is typically administered in tapering doses over 21 days and should be started within 72 hours of initiating antimicrobial therapy.
Alternative therapies are used when TMP-SMX cannot be tolerated or when treatment failure occurs. Intravenous pentamidine is an effective alternative but may cause significant toxicities including hypotension, arrhythmias, pancreatitis, dysglycemia, renal dysfunction, electrolyte abnormalities, and neutropenia. Other options include clindamycin plus primaquine, atovaquone, or trimethoprim plus dapsone. Primaquine should be avoided in patients with glucose-6-phosphate dehydrogenase deficiency.
Patients require close monitoring for clinical response, oxygenation status, and medication-related adverse effects. Complications include progressive respiratory failure, pneumothorax, concurrent pulmonary infections, and death. Mortality rates are approximately 10–20% among HIV-infected patients but may reach 30–50% in non-HIV immunocompromised individuals, largely due to delayed diagnosis and treatment. Early recognition and prompt therapy remain essential for improving outcomes.
Pneumocystis jiroveci is an opportunistic fungal pathogen whose natural habitat is the lung. It is an important cause of pneumonia in immunocompromised patients, especially individuals with HIV/AIDS. The disease is commonly referred to as Pneumocystis pneumonia (PCP). Although formerly known as Pneumocystis carinii, the organism infecting humans is now correctly termed Pneumocystis jiroveci. Despite advances in prophylaxis and antiretroviral therapy, PCP remains one of the most common opportunistic infections in HIV-infected patients.
The incidence of PCP has decreased substantially because of routine prophylaxis and improved HIV management. However, it still occurs frequently among patients with advanced immunosuppression. PCP has also been reported in patients receiving immunomodulatory therapies such as infliximab and etanercept. Extrapulmonary disease is uncommon, occurring in fewer than 3% of cases. Internationally, the reported incidence is considered low, although this is likely due to underdiagnosis. PCP is particularly important in HIV-infected infants, among whom it is responsible for a large proportion of pneumonia cases.
Major risk factors include HIV/AIDS with CD4 counts below 200/mm³, malignancy, long-term corticosteroid or immunosuppressive therapy, primary immunodeficiency syndromes, tobacco use, and severe malnutrition. Patients with organ transplants, hematologic malignancies, and severe combined immunodeficiency are also at increased risk. Because of these risks, prophylaxis is recommended for high-risk HIV-infected individuals and certain other immunocompromised populations.
Primary prophylaxis is indicated in HIV-infected patients with CD4 counts below 200/mm³ or in those with oropharyngeal candidiasis regardless of CD4 count. The preferred prophylactic regimen is one double-strength tablet of trimethoprim-sulfamethoxazole daily. Alternative regimens include reduced-dose TMP-SMX, dapsone-based regimens, nebulized pentamidine, or pyrimethamine combinations. Secondary prophylaxis is recommended for all patients recovering from PCP until immune reconstitution occurs.
Infection with P. jiroveci usually occurs early in childhood, and many healthy individuals harbor the organism in their lungs without disease. In immunocompromised hosts, defective cellular immunity—especially impaired CD4 T-cell function—prevents effective clearance of the organism. Activated macrophages become unable to eliminate the fungus, resulting in increased alveolar-capillary permeability and impaired gas exchange. This process produces hypoxemia, respiratory alkalosis, and diffuse interstitial pneumonia.
Patients usually present with nonspecific symptoms such as progressive exertional dyspnea, fever, dry cough, chest discomfort, chills, and weight loss. In HIV-infected individuals, the illness often develops gradually over days to weeks, whereas in non-HIV immunocompromised patients the disease may progress rapidly and severely. Hemoptysis is uncommon but may occur.
On physical examination, patients commonly have tachypnea, fever, and tachycardia. Pulmonary examination may be surprisingly normal in up to half of patients despite significant hypoxemia. Children with severe disease may exhibit cyanosis, nasal flaring, and intercostal retractions. Rare extrapulmonary manifestations can involve the central nervous system, thyroid, gastrointestinal tract, lymph nodes, eyes, and bone marrow.
Laboratory findings are nonspecific. Elevated lactate dehydrogenase (LDH) levels are common but not diagnostic. Serum β-D-glucan levels are frequently elevated. Arterial blood gas analysis typically demonstrates hypoxemia, respiratory alkalosis, and an increased alveolar–arterial oxygen gradient. Disease severity is often classified according to the degree of alveolar–arterial gradient elevation.
Chest radiography classically demonstrates bilateral diffuse perihilar infiltrates, although early disease may show a normal chest x-ray. Chest CT scanning is more sensitive and commonly reveals diffuse bilateral ground-glass opacities. Patients receiving aerosolized pentamidine prophylaxis may show upper-lobe infiltrates and are at increased risk for pneumothorax.
Definitive diagnosis requires identification of the organism in respiratory specimens. Fiberoptic bronchoscopy with bronchoalveolar lavage remains the diagnostic standard. Induced sputum may be used but has variable sensitivity. Histopathologic stains such as methenamine silver, toluidine blue, Giemsa, and immunofluorescent stains are used to identify cysts and trophozoites. More invasive procedures such as transbronchial biopsy or open-lung biopsy are reserved for difficult cases.
The differential diagnosis includes other causes of diffuse pneumonia and respiratory failure, including tuberculosis, cytomegalovirus pneumonia, viral pneumonias, Legionella infection, fungal pneumonias, pulmonary embolism, ARDS, congestive heart failure, and pulmonary involvement by Kaposi sarcoma or lymphoma.
Trimethoprim-sulfamethoxazole (TMP-SMX) is the treatment of choice for PCP. The recommended dose is 15–20 mg/kg/day of the trimethoprim component, administered orally or intravenously in divided doses. Treatment duration is 21 days in HIV-infected patients and 14 days in non-HIV patients. Clinical improvement usually occurs within several days, although clinicians should wait at least 4–8 days before concluding treatment failure.
Adjunctive corticosteroids significantly improve survival in patients with moderate to severe disease, particularly in HIV-associated PCP. Steroids are indicated in patients with a PaO₂ below 70 mm Hg or an alveolar–arterial gradient greater than or equal to 35 mm Hg. Prednisone is typically administered in tapering doses over 21 days and should be started within 72 hours of initiating antimicrobial therapy.
Alternative therapies are used when TMP-SMX cannot be tolerated or when treatment failure occurs. Intravenous pentamidine is an effective alternative but may cause significant toxicities including hypotension, arrhythmias, pancreatitis, dysglycemia, renal dysfunction, electrolyte abnormalities, and neutropenia. Other options include clindamycin plus primaquine, atovaquone, or trimethoprim plus dapsone. Primaquine should be avoided in patients with glucose-6-phosphate dehydrogenase deficiency.
Patients require close monitoring for clinical response, oxygenation status, and medication-related adverse effects. Complications include progressive respiratory failure, pneumothorax, concurrent pulmonary infections, and death. Mortality rates are approximately 10–20% among HIV-infected patients but may reach 30–50% in non-HIV immunocompromised individuals, largely due to delayed diagnosis and treatment. Early recognition and prompt therapy remain essential for improving outcomes.
0 Comments
